DN
DNLI
Denali Therapeutics Inc.
$21.66
+3.04%
$3.4B
No data for this timeframe.
Vol
Market Cap$3.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$1.7B
Inst. Activity14 buys / 10 sells
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001714899·Prev Close $21.02
Recent Activity
Jun 11, 2026
SEC
Mixed institutional activity in Denali Therapeutics for 2025-Q3: 3 large passive buyers (Morgan Stanley, UBS, BofA) adde
INST-CLUSTER — Impact 4/10
Jun 9, 2026
short_volume
Short Volume: DNLI — 63.0% short (0.5M / 0.7M)
Short: 471,731 | Exempt: 0 | TRF Vol: 748,646 | Short Ratio: 63.0% | Off-exchange volume (dark pool
Jun 3, 2026
Insider
FLATLEY JAY T was granted 19,226 shares
Director
Jun 3, 2026
Insider
FLATLEY JAY T was granted 6,408 shares
Director
Jun 3, 2026
Insider
Klein Peter S was granted 6,408 shares
Director
May 21, 2026
Press
Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease fail
Impact 7/10
May 7, 2026
SEC
Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S.
PRESS-RELEASE — Impact 7/10
Apr 3, 2026
SEC
Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-develop and co-commerc
8-K — Impact 5/10
Price Targets
$33.93
+56.7% upside
Strong Buy
Current $21.66
Low $20.00
Median $35.00
High $42.00
15 analysts
$20.00
$42.00
Analyst Ratings
11Strong Buy
12Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 14, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 11, 2026 | BTIG | REITERATE | Buy → Buy |
| May 8, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.53 ▼ -40.0% | $-0.89 — $0.36 | 26% YoY | 14 |
| Next Q | $-0.53 ▲ +19.7% | $-0.90 — $0.19 | 28% YoY | 14 |
| Current FY | $-2.32 ▲ +9.2% | $-2.97 — $-1.21 | 22% YoY | 14 |
| Next FY | $-2.48 ▲ +4.1% | $-2.89 — $-1.80 | -7% YoY | 15 |
Latest Reports
MIXED
INST-CLUSTER
4/10
Mixed institutional activity in Denali Therapeutics for 2025-Q3: 3 large passive buyers (Morgan Stanley, UBS, BofA) adde
Jun 11, 2026
BEARISH
Press
7/10
Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease fail
May 21, 2026
BULLISH
PRESS-RELEASE
7/10
Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S.
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $250.3M | — |
| BAILLIE GIFFORD & CO | $231.7M | — |
| Temasek Holdings (Private) Ltd | $134.6M | ADD |
| STATE STREET CORP | $120.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $118.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | FLATLEY JAY | A | $0.00 |
| Jun 3, 2026 | FLATLEY JAY | A | $0.00 |
| Jun 3, 2026 | Klein Peter | A | $0.00 |
| Jun 3, 2026 | Krognes Steve | A | $0.00 |
| Jun 3, 2026 | Klein Peter | A | $0.00 |
50 institutional holders with $1.7B total value (90,789,700 shares) as of 2026-Q1. Top holders: BlackRock,, BAILLIE, Temasek. Net buying activity: 14 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 13,034,434 | $250.3M | 14.4% | — |
| 2 | BAILLIE GIFFORD & CO | 12,066,479 | $231.7M | 13.4% | — |
| 3 | Temasek Holdings (Private) Ltd | 7,012,974 | $134.6M | 7.8% | ADD +30.9% |
| 4 | STATE STREET CORP | 6,272,001 | $120.4M | 6.9% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 6,147,957 | $118.0M | 6.8% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,120,160 | $117.5M | 6.8% | — |
| 7 | FMR LLC | 4,575,374 | $87.8M | 5.1% | — |
| 8 | GOLDMAN SACHS GROUP INC | 4,407,255 | $84.6M | 4.9% | — |
| 9 | BAKER BROS. ADVISORS LP | 3,731,695 | $71.6M | 4.1% | — |
| 10 | Holocene Advisors, LP | 3,195,429 | $61.4M | 3.5% | DOUBLED +677.8% |
| 11 | DIMENSIONAL FUND ADVISORS LP | 2,692,175 | $51.7M | 3.0% | — |
| 12 | Pictet Asset Management Holding SA | 2,558,865 | $48.4M | 2.8% | ADD +92.5% |
| 13 | Capital Research Global Investors | 2,514,588 | $48.3M | 2.8% | TRIM -32.6% |
| 14 | ALLIANCEBERNSTEIN L.P. | 2,893,618 | $47.8M | 2.8% | — |
| 15 | Alyeska Investment Group, L.P. | 1,941,123 | $37.3M | 2.1% | DOUBLED +125.9% |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,207,399 | $23.2M | 1.3% | — |
| 17 | BANK OF AMERICA CORP /DE/ | 1,134,183 | $21.8M | 1.3% | ADD +47.8% |
| 18 | MORGAN STANLEY | 1,104,757 | $21.2M | 1.2% | TRIM -27.8% |
| 19 | Artisan Partners Limited Partnership | 1,099,719 | $21.1M | 1.2% | NEW |
| 20 | MARSHALL WACE, LLP | 991,268 | $19.0M | 1.1% | ADD +29.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Pictet Asset Management Holding SA | ADD | 1,329,108 | 2,558,865 | +92.5% | $48.4M | 2026-Q1 |
| Capital Research Global Investors | TRIM | 3,729,244 | 2,514,588 | -32.6% | $48.3M | 2026-Q1 |
| Alyeska Investment Group, L.P. | DOUBLED | 859,108 | 1,941,123 | +125.9% | $37.3M | 2026-Q1 |
| Artisan Partners Limited Partnership | NEW | — | 1,099,719 | — | $21.1M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 763,892 | 991,268 | +29.8% | $19.0M | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 114,082 | 364,082 | +219.1% | $7.0M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | TRIM | 450,985 | 285,820 | -36.6% | $5.2M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 184,238 | 125,442 | -31.9% | $2.4M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 70,830 | 99,503 | +40.5% | $1.9M | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | TRIM | 128,800 | 95,193 | -26.1% | $1.8M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 180,221 | 89,534 | -50.3% | $1.7M | 2026-Q1 |
| POLEN CAPITAL MANAGEMENT LLC | DOUBLED | 26,900 | 65,301 | +142.8% | $1.3M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 38,669 | 50,900 | +31.6% | $977.3K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 1,265 | 25,935 | +1950.2% | $498.0K | 2026-Q1 |
| XPONANCE LLC | ADD | 10,497 | 13,240 | +26.1% | $254.2K | 2026-Q1 |
| CAPSTONE INVESTMENT ADVISORS, LLC | TRIM | 38,812 | 12,963 | -66.6% | $248.9K | 2026-Q1 |
| CWM, LLC | ADD | 2,606 | 4,651 | +78.5% | $89.3K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | 3,915,951 | 2,464,146 | -37.1% | $47.3K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | ADD | 1,449 | 2,424 | +67.3% | $46.5K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | 627 | 927 | +47.8% | $17.8K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 90 | 280 | +211.1% | $5.4K | 2026-Q1 |
| ExodusPoint Capital Management, LP | EXIT | 1,023,253 | 0 | -100.0% | $0.00 | 2026-Q1 |
| NORGES BANK | EXIT | 5,119,622 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 1,700,000 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Temasek Holdings (Private) Ltd | ADD | 5,355,832 | 7,012,974 | +30.9% | $115.8M | 2025-Q4 |
8 unique insiders with 17 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | FLATLEY JAY T | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | FLATLEY JAY T | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | Klein Peter S | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | Krognes Steve E. | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | Klein Peter S | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | Schenkein David P | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | Van Hauwermeiren Timothy | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | Thornberry Nancy | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | Van Hauwermeiren Timothy | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | Cook Jennifer E. | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | Krognes Steve E. | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | Cook Jennifer E. | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | Thornberry Nancy | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | Schenkein David P | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 19,226 | — | — |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 6,408 | — | — |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 19,226 | — | — |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.3/10.
MIXED
INST-CLUSTER
4/10
Mixed institutional activity in Denali Therapeutics for 2025-Q3: 3 large passive buyers (Morgan Stan
Jun 11, 2026
BULLISH
PRESS-RELEASE
7/10
Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FD
May 7, 2026
NEUTRAL
8-K
5/10
Denali Therapeutics announced that Takeda has terminated their 2018 collaboration agreement to co-de
Apr 3, 2026
BEARISH
7/10
Denali Therapeutics and Biogen announced that the Phase 2b LUMA study of BIIB122 in early-stage Park
May 21, 2026
MIXED
6/10
Denali Therapeutics announced that Takeda has terminated their collaboration on DNL593, an investiga
Apr 3, 2026
BULLISH
9/10
Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the fir
Mar 25, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 25 analysts: 11 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$33.93 mean target
+56.7% upside
Strong Buy (1.16)
$20.00 Low
$42.00 High
| Metric | Value |
|---|---|
| Current Price | $21.66 |
| Target Low | $20.00 |
| Target Mean | $33.93 |
| Target Median | $35.00 |
| Target High | $42.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.16) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.53 | $-0.89 | $0.36 | 26.0% | -40.0% | 5↑ 2↓ | $0.0B | 0.0% | 14 |
| Next Q 2026-09-30 |
$-0.53 | $-0.90 | $0.19 | 27.8% | +19.7% | 6↑ 2↓ | $0.0B | 0.0% | 14 |
| Current FY 2026-12-31 |
$-2.32 | $-2.97 | $-1.21 | 22.0% | +9.2% | 11↑ 2↓ | $0.0B | 0.0% | 14 |
| Next FY 2027-12-31 |
$-2.48 | $-2.89 | $-1.80 | -7.0% | +4.1% | 10↑ 0↓ | $0.1B | 176.0% | 15 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.533 | |
| 7d ago | $-0.533 | |
| 30d ago | $-0.380 | -0.152 |
| 60d ago | $-0.415 | -0.117 |
| 90d ago | $-0.559 | +0.026 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 14, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | BTIG | REITERATE | Buy | Buy |
| May 8, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 7, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 26, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Peer Perform |
| Feb 6, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 12 | 2 | 0 | 0 | 92% | |
| May 1, 2026 | 11 | 12 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 11 | 12 | 2 | 0 | 0 | 92% | |
| Mar 1, 2026 | 11 | 12 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 11 | 12 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: DNLI — 63.0% short (0.5M / 0.7M)
Short: 471,731 | Exempt: 0 | TRF Vol: 748,646 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: DNLI — 84.9% short (0.7M / 0.8M)
Short: 673,313 | Exempt: 0 | TRF Vol: 793,314 | Short Ratio: 84.9% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: DNLI — 77.8% short (0.4M / 0.6M)
Short: 442,955 | Exempt: 810 | TRF Vol: 569,146 | Short Ratio: 77.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: DNLI — 62.9% short (0.4M / 0.6M)
Short: 379,990 | Exempt: 400 | TRF Vol: 603,693 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: DNLI — 73.1% short (0.4M / 0.5M)
Short: 378,860 | Exempt: 0 | TRF Vol: 518,044 | Short Ratio: 73.1% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: DNLI — 59.7% short (0.6M / 1.0M)
Short: 590,435 | Exempt: 101 | TRF Vol: 989,582 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: DNLI — 71.9% short (0.9M / 1.3M)
Short: 930,542 | Exempt: 5,550 | TRF Vol: 1,294,613 | Short Ratio: 71.9% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
<p>CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IBSoatANZG
May 19, 2026
short_volume
Short Volume: DNLI — 69.7% short (0.5M / 0.7M)
Short: 467,183 | Exempt: 245 | TRF Vol: 670,267 | Short Ratio: 69.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: DNLI — 68.9% short (0.5M / 0.8M)
Short: 518,412 | Exempt: 100 | TRF Vol: 752,853 | Short Ratio: 68.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: DNLI — 71.4% short (0.5M / 0.7M)
Short: 516,361 | Exempt: 37 | TRF Vol: 723,613 | Short Ratio: 71.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: DNLI — 79.0% short (0.6M / 0.8M)
Short: 646,100 | Exempt: 25 | TRF Vol: 817,677 | Short Ratio: 79.0% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: DNLI — 59.2% short (0.5M / 0.9M)
Short: 506,346 | Exempt: 148 | TRF Vol: 855,556 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: DNLI — 56.8% short (0.4M / 0.8M)
Short: 441,006 | Exempt: 0 | TRF Vol: 776,119 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
<p align="left">SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial resul
Mar 24, 2026
FDA
AVLAYAH
Original Approval — Type 1 - New Molecular Entity — INJECTION
Mar 24, 2026
FDA
AVLAYAH
Original Approval — Type 1 - New Molecular Entity — INJECTION
Mar 24, 2026
FDA
AVLAYAH
Original Approval — Type 1 - New Molecular Entity — INJECTION